Media coverage about Vertex Pharmaceuticals (NASDAQ:VRTX) has trended somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vertex Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the pharmaceutical company an impact score of 46.0147740828684 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media stories that may have effected Accern’s rankings:
- Why the Earnings Streak Will Continue for Vertex Pharmaceuticals (VRTX) (finance.yahoo.com)
- Vertex Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VRTX) : October 10, 2017 (finance.yahoo.com)
- Valero Energy Corporation (VLO) Weigh On Beatable Move- Vertex Pharmaceuticals Incorporated (VRTX) – Investing News Update (investingbizz.com)
- Buy sentiment on Healthcare Stock: Vertex Pharmaceuticals Incorporated (VRTX) – Street Observer (press release) (streetobserver.com)
- Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VRTX-US : October 9, 2017 (finance.yahoo.com)
Shares of Vertex Pharmaceuticals (NASDAQ VRTX) opened at 154.02 on Thursday. The stock’s 50 day moving average price is $154.29 and its 200 day moving average price is $135.25. The stock has a market capitalization of $38.83 billion, a P/E ratio of 147.95 and a beta of 1.73. Vertex Pharmaceuticals has a one year low of $71.46 and a one year high of $167.85.
A number of equities analysts have issued reports on VRTX shares. Vetr raised Vertex Pharmaceuticals from a “strong sell” rating to a “strong-buy” rating and set a $156.00 target price on the stock in a research report on Tuesday, July 18th. Royal Bank Of Canada began coverage on Vertex Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $175.00 price target for the company. Jefferies Group LLC reiterated a “buy” rating and issued a $185.00 price target (up from $155.00) on shares of Vertex Pharmaceuticals in a report on Wednesday, July 19th. Credit Suisse Group boosted their price target on Vertex Pharmaceuticals from $125.00 to $195.00 and gave the company an “outperform” rating in a report on Wednesday, July 19th. Finally, Zacks Investment Research upgraded Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $174.00 price target for the company in a report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, twenty-three have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $167.04.
ILLEGAL ACTIVITY NOTICE: This report was reported by Community Financial News and is the property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.com-unik.info/2017/10/12/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-vertex-pharmaceuticals-vrtx-stock-price.html.
In other Vertex Pharmaceuticals news, SVP Paul M. Silva sold 43,443 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $161.07, for a total transaction of $6,997,364.01. Following the transaction, the senior vice president now directly owns 26,516 shares in the company, valued at $4,270,932.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jeffrey M. Leiden sold 216,624 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $160.96, for a total value of $34,867,799.04. Following the transaction, the chief executive officer now owns 400,266 shares in the company, valued at $64,426,815.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 518,357 shares of company stock worth $83,154,633. Corporate insiders own 1.80% of the company’s stock.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
What are top analysts saying about Vertex Pharmaceuticals Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vertex Pharmaceuticals Incorporated and related companies.